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Abstract
Background: Methadone treatment was introduced in Taiwan in 2006 as a harm-reduction program in response
to the human immunodeficiency virus (HIV), which is endemic among Taiwanese heroin users. The present study
was aimed at examining the clinical and behavioral characteristics of methadone patients in northern Taiwan
according to their HIV status.
Methods: The study was conducted at four methadone clinics. Participants were patients who had undergone
methadone treatment at the clinics and who voluntarily signed a consent form. Between August and November
2008, each participant completed a face-to-face interview that included questions on demographics, risk behavior,
quality of life, and psychiatric symptoms. Data on HIV and hepatitis C virus (HCV) infections, methadone dosage,
and morphine in the urine were retrieved from patient files on the clinical premises, with permission of the
participants.
Results: Of 576 participants, 71 were HIV positive, and 514 had hepatitis C. There were significant differences
between the HIV-positive and HIV-negative groups on source of treatment payment, HCV infection, urine test
results, methadone dosage, and treatment duration. The results indicate that HIV-negative heroin users were more
likely to have sexual intercourse and not use condoms during the 6 months prior to the study. A substantial
percent of the sample reported anxiety (21.0%), depression (27.2%), memory loss (32.7%), attempted suicide
(32.7%), and administration of psychiatric medications (16.1%). There were no significant differences between the
HIV-positive and HIV-negative patients on psychiatric symptoms or quality of life.
Conclusions: HIV-positive IDUs were comorbid with HCV, indicating the need to refer both HIV- and HCV-infected
individuals for treatment in methadone clinics. Currently, there is a gap between psychiatric/psychosocial services
and patient symptoms, and more integrated medical services should be provided to heroin-using populations.
Background
Many countries in the world are grappling with pro-
blems of drug use, and Taiwan is no exception. In the
past decade, there has been a resurgence of opiate (her-
oin) use in Taiwan, and this increase poses great chal-
lenges for health professionals and policy makers.
According to the Taiwan Center for Disease Control
(CDC), the number of people using heroin has increased
during the past 5 years, and the incidence of contracting
the human immunodeficiency virus (HIV) and/or the
hepatitis C virus (HCV) has increased tenfold [1]. At the
end of 2009, the proportion of HIV cases related to Tai-
wanese injection drug users (IDUs) was 34% [2], and the
percentage of IDUs that had contracted HCV was about
80-90% [3]. Because oral ingestion of methadone can
help heroin users prevent HCV and HIV infection and
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managing withdrawal syndromes and cravings [4-6],
methadone maintenance treatment was adopted in
Taiwan, and it expanded rapidly as part of a harm-
reduction policy aimed at stemming the spread of HIV
[7]. According to the Taiwan CDC (2010), there are
currently 100 hospital clinics providing methadone
treatment, supplemented by 22 satellite community
health centers. Together, these units serve more than
11,000 patients.
Because in Taiwan the primary goal of methadone
maintenance treatment is to stem the spread of HIV
rather treat heroin dependence, the use or possession of
heroin is still illegal. Offenders can choose either to take
methadone for at least one year as an outpatient in a
hospital or be incarcerated in a residential detoxification
or rehabilitation center administered by the Taiwan
Ministry of Justice. Although methadone maintenance is
widely acknowledged as an effective treatment for her-
oin dependence and the reduction of HIV infections in
Western societies [5], only recently has it become estab-
lished in Taiwan, where its utility has been novel to psy-
chiatrists, methadone patients and stakeholders. Thus, it
is important to determine who participates in metha-
done treatment in Taiwan and if there are differences in
the HIV status of heroin users. The present study was
conducted to examine HIV serostatus in relation to the
demographics, clinical characteristics, risk behavior, and
quality of life of methadone patients in northern
Taiwan.
Methods
Participants and procedure
The participants were recruited through four methadone
clinics in New Taipei City, Taipei city, Keelung and I-
Lan county, all in northern Taiwan. The inclusion cri-
teria for participants were as follows: at least 18 years
old, literate, using heroin in the past 6 months, and cur-
rently enrolled in a methadone treatment program. The
research was approved by the Institutional Review Board
of Human Subjects Protection at Taipei Medical Univer-
sity (approval number: P960205) and Taipei City Hospi-
tal (approval number: TCHIRB-970404-E). After
explaining the purpose of the research to the methadone
patients, the participants voluntarily signed a consent
form and took a face-to-face interview, which was con-
ducted between August and November 2008. Interviews
were conducted in a private room provided by the clinic
and took approximately 15 minutes to complete. At the
time of data collection, participants had already been
engaged in methadone treatment. All participants
received remuneration of 100 Taiwan dollars (approxi-
mately 3 US dollars) for their participation.
Measures
A semi-structured questionnaire was used to obtain
information about demographics, quality of life, HIV
risk behavior, and psychiatric symptoms. Their treat-
ment right, anonymity and confidentiality were assured
to participants so that questions can be responded com-
fortably and truthfully.
Demographics and clinical characteristics
The demographic items asked about the participant’s age,
age at first heroin use, gender, education, source of metha-
done payment, and employment. Before admission to
methadone treatment, the patients were asked by their
physician to take tests for HIV, HCV, and morphine if
they had not previously tested positive for the factor. The
psychiatrists’ determination of the initial daily dose of
methadone and the payment was based on the patients’
drug-using history and the results of the tests mentioned
above. For patients confirmed as HIV positive, the cost of
the methadone treatment was fully covered by the Taiwan
government. All patients were reassessed monthly so their
doctor could adjust the daily dose. After obtaining patient
consent, records for the variables examined in the study
were retrieved from patient files on the hospital’s compu-
ter systems. The data included HIV status, HCV status,
morphine from urine tests, and methadone dosage at
intake. Data from the urine tests and methadone dosage
were also collected at the times of the interview.
Quality of life
We used the World Health Organization Quality of Life
Assessment-Brief Version (WHOQOL-BREF), which was
developed to measure overall quality of life and general
health status [8,9]. The WHOQOL-BREF measures four
health domains (physical, psychological, social and envir-
onmental). The instrument has shown excellent internal
consistency (Cronbach’sa l p h a=0 . 9 7 ) ,a sw e l la sg o o d
test-retest reliability over 2 weeks for the four domains
(0.68 to 0.85) [9]. In the current study, Cronbach’sa l p h a
was 0.91. The four-domain structure was validated by
exploratory and confirmatory factor analysis, with factor
loadings > 0.40 for the retained items and CFI > 0.90 [9].
These latter results demonstrate adequate validity.
Risk behavior and psychiatric symptoms
Respondents indicated their risk behavior 6 months per-
iod before the interview. Sex-related and drug-related
risk behavior were assessed by five items: 1) having sex-
ual coitus during the last 6 months, 2) using a condom
during last sexual intercourse, 3) frequency of condom
use during the last 6 months, 4) heroin use during last
6 months, and 5) needle sharing during last 6 months.
Psychiatric symptoms were measured in the past
30 days before the interview by five questions covering
1) anxiety, 2) depression, 3) memory loss, 4) attempted
suicide, and 5) psychiatric medications prescribed.
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Statistical analyses were conducted using SPSS version
16.0 [10]. Differences between the two HIV groups in
the categorical proportions for demographic factors,
clinical characteristics, types of risk behavior, and psy-
chiatric symptoms were evaluated using chi-square tests,
or Fisher exact tests if the sample was small. Compari-
s o n so ft h et w oH I Vg r o u p so nc o n t i n u o u sv a r i a b l e s ,
including age, age at first heroin use, methadone dose,
treatment duration and quality of life were performed
using independent sample t tests. Items with missing
values were omitted from the analysis. The criterion for
statistical significance was set at p < 0.05, two-tailed.
Results
Demographics and clinical characteristics
Of the 599 patients recruited for the study, 576 com-
pleted the consent forms and interviews. Of the latter,
71 (12%) were HIV positive. Table 1 presents participant
demographics and clinical characteristics according
to HIV status. The mean age of the participants
was 40.6 years, and the mean age at first heroin use was
27.2 years. Treatment fee was fully covered by govern-
ment for the HIV-positive patients in contrast to 35.4%
for the HIV-negative group. In addition, 71% had com-
pleted 9 years of compulsory education, and 66% were
employed at the time of assessment. No other significant
differences were found between the demographics of the
HIV-positive and HIV-negative participants.
The two HIV groups differed significantly on HCV and
morphine at intake and on methadone dosage at interview
(Table 1). Interestingly, 514 (93%) were HCV positive, and
every HIV-positive patient tested positive for HCV. In
addition, 92% of the HIV-negative participants were posi-
tive for HCV. The between-HIV-group difference was sig-
nificant for HCV prevalence by Fisher’s exact test (p <
0.01). The urine tests showed that more than 70% of the
patients in the HIV-negative group tested positive for mor-
phine at intake, compared to 55% in the HIV-positive
group, c
2(1, N = 544) = 6.08, p < 0.05. The average dose of
methadone at intake was 38.5 ± 20.3 mg and the dosage
increased to 49.8 ± 31.7 mg by the time of the interview.
At that time, the mean dose of methadone for the
HIV-positive group was significantly higher than for the
HIV-negative group, t(543) = 2.95, p < 0.01. Also, the HIV-
positive group spent on average significantly more days in
methadone treatment than the HIV-negative group (218
days vs. 179 days); t(553) = 2.05, p < 0.05.
HIV risk behavior, psychiatric symptoms, and
quality of life
Table 2 shows the differences between the HIV-positive
and HIV-negative groups on risk behavior, psychiatric
symptoms, and quality of life. The groups differed
Table 1 Demographic and clinical characteristics as a function of the HIV status of methadone patients from four
hospitals (N = 576)
HIV-positive HI- negative Total
n = 71 (12%) n = 505 (88%)
Age (years, mean ± SD) 39.3 ± 7.8 40.8 ± 9.4 40.6 ± 9.3
Age at first heroin use (years, mean ± SD) 25.9 ± 6.2 27.4 ± 7.5 27.2 ± 7.4
Gender Male Female 67 (90%) 7 (10%) 438 (87%) 64 (13%) 503 (87%) 73 (13%)
Source of treatment fee Self-paid 0 (0%) 330 (65.3%) 330 (57.3%)**
Government sponsor 71 (100%) 175 (35.4%) 246 (42.7%)
Education Less than 9 years At least 9 years 22 (31%) 49 (69%) 142 (28%) 363 (72%) 164 (29%) 412 (71%)
Employed (n = 549)
a No 30 (44%) 157 (33%) 187 (34%)
Yes 38 (56%) 324 (67%) 362 (66%)
HCV (n = 552)
a Negative 0 (0%) 38 (8%) 38 (7%)**
Positive 66 (100%) 442 (92%) 514 (93%)
Morphine at intake (n = 545)
a Negative 31 (45%) 145 (31%) 176 (32%)*
Positive 38 (55%) 331 (69%) 369 (68%)
Morphine at interview (n = 506)
a Negative 48 (76%) 294 (66%) 342 (68%)
Positive 15 (24%) 149 (34%) 164 (32%)
Average methadone dose at intake (mg, mean ± SD) 37.5 ± 20.4 38.7 ± 20.3 38.5 ± 20.3
Average methadone dose at interview (mg, mean ± SD) 60.4 ± 35.0 48.2 ± 30.9 49.8 ± 31.7**
Time from intake to interview (days, mean ± SD) 218 ± 164 179 ± 146 184 ± 149*
*p < 0.05.
**p < 0.01.
aMissing values were omitted from the statistical analyses.
Note: c
2 and t tests were used to examine differences between the HIV groups on categorical and continuous variables respectively. A Fisher exact test was
performed to examine the relationship between HCV and HIV.
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6 months, c2(1, N = 528) = 19.7, p <.01, condom use at
last sexual encounter, c2(1, N = 460) = 15.301, p < 0.01,
frequency of condom use within the last 6 months, c2
(2, N = 390) = 13.164, p < 0.01, and heroin injection
within the last 6 months, c2(1, N = 518) = 4.309, p <
0.05. Specifically, 90% of the HIV-negative patients who
were sexually active had sexual intercourse within the
last 6 months compared to 70% of the corresponding
HIV-positive patients. Likewise, 54% of the sexually-
active HIV-negative patients did not use condoms dur-
ing their last sexual intercourse, compared with 23% of
the corresponding HIV-positive patients. Whereas 42%
of the sexually active HIV-positive patients reported that
they always or frequently used condoms during the last
6 months, 24% reported that they used condoms only
sometimes during this period, and 34% reported that
they never used them during this period (Table 2). In
contrast, 18%, 22%, and 60% of HIV-negative patients
reported that they always/frequently, sometimes, and
never used condoms during the last 6 months,
respectively.
The results show that 88% of the participants reported
that they had injected heroin within the last 6 months.
This percentage was higher in the HIV-negative group
t h a nt h eH I V - p o s i t i v eg r o u p ,c2(1, N = 518) = 4.309,
p < 0.05. In addition, 94% of the patients reported that
they rarely or never shared their syringes with others
during the last 6 months. However, 7 HIV-positive par-
ticipants reported sharing syringes during this period.
Regarding psychiatric symptoms 30 days prior to the
interview, 21% of the participants experienced anxiety,
Table 2 HIV risk behavior, psychiatric symptoms, and quality of life as a function of HIV status
HIV-positive HIV-negative Total
Sexual Risk
Engaging in sex within last 6 months (n = 528)
a Yes 47 (70%) 413 (90%) 460 (87%)**
No 20 (30%) 48 (10%) 68 (13%)
Condom use at last sexual encounter (n = 460) Yes 36 (77%) 192 (46%) 228 (50%)**
No 11 (23%) 221 (54%) 232 (50%)
Frequency of condom use within last 6 months (n = 391)
a Always/Frequently 16 (42%) 66 (18%) 82 (21%)**
Often/Sometimes 9 (24%) 76 (22%) 85 (22%)
Few/Never 13 (34%) 211 (60%) 224 (57%)
Drug-related risk
Heroin injection within last 6 months (n = 518)
a Yes 54 (81%) 403 (89%) 457 (88%)*
No 13 (19%) 48 (11%) 61 (12%)
Sharing syringes during last 6 months (n = 457)
a Always/Frequently 2 (4%) 3 (1%) 5 (1%)
Often/Sometimes 5 (9%) 19 (5%) 24 (5%)
Few/Never 47 (87%) 381 (94%) 428 (94%)
Psychiatric Symptoms (n = 523)
a
Anxiety No 51 (78.5%) 362 (79.0%) 413 (79.0%)
Yes 14 (21.5%) 96 (21.0%) 110 (21.0%)
Depression No 47 (72.3%) 334 (72.9%) 381 (72.8%)
Yes 18 (27.7%) 124 (27.1%) 142 (27.2%)
Memory loss No 46 (70.8%) 306 (66.8%) 352 (67.3%)
Yes 19 (29.2%) 152 (33.2%) 171 (32.7%)
Attempted suicide No 46 (70.8%) 306 (66.8%) 352 (67.3%)
Yes 19 (29.2%) 152 (33.2%) 171 (32.7%)
Psychiatric medication prescribed No 52 (80.0%) 386 (84.5%) 438 (83.9%)
Yes 13 (20.0%) 71 (15.5%) 84 (16.1%)
Quality of life (n = 551)
a Range 0 to 100 (mean ± SD) (mean ± SD) (mean ± SD)
Physical domain 58.22 ± 17.57 56.80 ± 16.07 56.98 ± 16.25
Psychological domain 45.27 ± 15.91 48.91 ± 14.77 48.46 ± 14.95
Social domain 50.51 ± 19.05 54.02 ± 18.54 53.58 ± 18.62
Environment domain 53.42 ± 16.79 51.45 ± 17.13 51.69 ± 17.08
*p < 0.05.
**p < 0.01.
aMissing values were omitted from the statistical analyses.
Note: c
2 and t tests were used to examine differences between the HIV groups on categorical and continuous variables respectively. A Fisher exact test was
performed to examine the relationship between syringe sharing and HIV.
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memory, 32.7% attempted suicide, and 16.1% took psy-
chiatric medications within the past 30 days. No signifi-
cant differences were found between psychiatric
symptoms and HIV status.
As for quality of life, of the four domains measured by
the WHOQOL-BREF, the methadone patients scored
lowest on psychological (mean = 48.46) and highest on
physical (mean = 56.98). However, no significant differ-
ences in quality of life were found between the HIV-
positive and HIV-negative groups on the overall scale or
any of the four domains.
Discussion
This study was aimed at determining the demographics
and clinical characteristics of methadone patients in
northern Taiwan as a function of their HIV status. We
found no demographic differences between the HIV-
positive and HIV-negative groups. The demographics of
the patients in the present study were similar to those
in other studies of heroin use [11], except that our
respondents were about 5 to 7 years older than those in
the other studies when they began using heroin [5,12].
But, the mean age of first heroin use in this study (27.2
± 7.4 years) was similar to a previous study (25.4 ± 6.7
years) conducted among 155 treatment-seeking heroin
abusers in Taiwan [13].
With respect to clinical characteristics, there were sig-
nificant differences between our HIV-positive and HIV-
negative groups on HCV infection, morphine in the
u r i n ea n dm e t h a d o n ed o s a g ea tt h et i m eo ft h ei n t e r -
view. Because IDUs commonly share injection equip-
ment (needles), and HCV and HIV are transmitted
mainly through blood and serum, IDUs are highly sus-
ceptible to HCV and HIV [4,5,14,15]. Global estimates
of the prevalence of HCV infection in IDUs have been
highest for Asia [16]. In most Asian countries, including
Taiwan, drug users are tested for HCV but receive no
treatment for it [17]. As they do for HIV testing and
counseling of men who have sex with other men, hospi-
tals should design and implement programs for the
behavior counseling and education programs about
HCV and health generally.
In our study, we found that psychiatrists increased the
average daily dose of methadone to 60 mg in HIV-posi-
tive patients but not in HIV-negative patients. Also, the
HIV-positive patients started using heroin earlier and
stayed longer in treatment. There are two plausible
explanations. One is that the difference in dosing is
because the severity of dependence between these two
groups may not be the same at the intake. Another
explanation may reflect the fact that since the harm-
reduction policy was initiated by the Taiwan govern-
ment in 2006, psychiatrists in Taiwan have been
professionally trained and educated in a way that treats
methadone as an HIV prevention strategy rather than as
a treatment for substance abuse. Policy makers may
want to reconceptualize methadone as a relatively effec-
tive treatment for opioid dependence, given that the
number of reports of new HIV cases related to heroin
use has been decreasing in Taiwan [2]. A previous study
found that methadone treatment can result in longer
treatment stays and an opioid abstinence rate twice as
high as with psychosocially enriched detoxification [18].
Further evidence of the effectiveness of methadone
treatment comes from our finding that prescribing
60 mg or more of methadone can result in a longer stay
in treatment than prescribing a lower dose. This finding
is consistent with a previous study of 428 methadone
patients in which it was found that a daily methadone
dose of 60 mg/day or above was associated with longer
retention in treatment [19]. Hence, both policy makers
and psychiatrists should redefine methadone treatment
as a medication-assisted therapy that is aimed at, but
not limited to, the reduction of HIV infection among
heroin users.
Another policy issue is how much heroin users should
pay for their methadone treatment if the policy goal is
to reduce the harm caused by drug use. According to
Taiwan’s HIV Prevention Act, anti-retroviral therapy
(commonly known as cocktail therapy) and methadone
treatment for HIV-positive patients are fully reimbursed
by the Taiwan Department of Health. Combined with
our finding that the average duration of treatment was
longer for the HIV-positive group than for the HIV-
negative group, this finding indirectly supports the
hypothesis that people stay longer in methadone treat-
ment if it is free. A previous study of 557 injection drug
users likewise found that free treatment can result in a
greater likelihood of patients’ remaining in treatment for
a minimum of 90 days; longer continuation of treatment
was also associated with better patient outcomes [20].
Policy makers in Taiwan may want to explore further
whether free treatment can result in better outcomes in
terms of reducing the bio-psycho-social harm of heroin
use.
Our results for risk behavior show that the HIV-nega-
tive participants were more likely to be sexually active
and less likely to use condoms during sexual intercourse
than the HIV-positive participants. These results are
consistent with some Western studies [21,22] suggesting
that most HIV-infected drug users avoid or abstain
from risky behavior that may result in the transmission
of HIV. There have been mixed results, however, con-
cerning whether HIV-infected individuals actually
engage in safer behavior. Some studies found that HIV-
positive drug users continued their risky practices. For
example, a study on a small sample of 50 HIV-positive
Lee et al. Substance Abuse Treatment, Prevention, and Policy 2011, 6:6
http://www.substanceabusepolicy.com/content/6/1/6
Page 5 of 7IDUs found that 66% continued to engage in either sex-
related or drug-related risky sexual behavior even after
they were aware of being HIV-positive, and 42%
admitted to having engaged in both types of risk beha-
vior [23]. In another study of 3723 HIV-infected per-
sons, about 79% of the 304 participants who reported
injecting drugs in the past year were sexually active,
50% had multiple partners, and 52% engaged in unpro-
tected intercourse during the past 3 months. We also
found that 21 out of our 71 HIV-infected respondents
were continuing to have sexual coitus without always
using condoms. Thus, it is imperative for substance use
programs to begin setting treatment goals and adopting
treatment strategies that encourage HIV-infected indivi-
duals to always adopt safer sexual practices. These inter-
ventions must also be sensitive to the special needs and
circumstances of the drug-using population. HIV risk-
reduction and behavioral counseling have not yet been
incorporated in methadone treatment programs in
Taiwan. If personnel and funding are limited, we recom-
mend that such counseling restrict its focus to HIV-
positive heroin users at methadone clinics.
Providing methadone to heroin users not only limits
the needle sharing that can stem the spread of infectious
diseases, but it also treats addiction and the drug-related
effects of heroin dependence, which affects the drug
user’s quality of life. The mean quality-of-life scores in
our study ranged from 48.46 to 56.98 on a 0 to 100
scale. Our respondents scored 2-6 points lower than
people with hepatitis and 13 points lower than the gen-
eral population of Taiwan [25]. The lower quality-of-life
mean for heroin users may partially be the effect of
labeling, as well as the strong social stigma attached to
drug addiction [26]. Drug users also are likely to have
poor social/family support, which can negatively affect
their mental health and social skills, thereby further low-
ering their quality of life [27]. In our study, we found no
differences in quality of life between the HIV-positive
and HIV-negative patients. However, there may be real
differences that were obscured by the labeling and
stigma mentioned above. In any case, the medical com-
munity should consider eliminating discrimination
toward drug users and have more empathy for Taiwa-
nese who suffer from the effects of heroin use.
Examination of the psychiatric symptom data reveals
that one fourth to one third of the respondents receiv-
ing methadone treatment needed additional medical ser-
vices for their psychiatric problems. Consistent with
other studies [28], the rates of depression and depressive
symptoms were similar for our HIV-positive and HIV-
negative groups. Our results indicate a high prevalence
of psychiatric comorbidity among Taiwan heroin users,
and a substantial number of our respondents had
received no treatment for their anxiety, depression, or
suicide attempts. These symptoms might be attributable
to psychosocial or behavioral factors such as poor social
support, a low sense of personal control, low socioeco-
nomic status, and low self-esteem [28]. Our results high-
light the importance of combining methadone treatment
with psychosocial services, which are currently not
included in substance abuse treatment. Examples of the
services needed to alleviate depression and anxiety are
the strengthening of family support, the elicitation of
emotional catharsis, and cognitive psychotherapy.
The present study has a few limitations. As our partici-
p a n t sw e r er e c r u i t e df r o me x c l u s i v e l yf o u rm e t h a d o n e
clinics in northern Taiwan, they may not constitute a
representative sample of Taiwanese heroin users. Even
though our clinic-based sample was large, our partici-
pants may differ in some relevant respects from the gen-
eral population of heroin users. Second, because risk
behavior was assessed through a questionnaire, it was not
possible to validate whether the patients answered the
questions truthfully. We attempted to reduce this pro-
blem by providing our participants with confidentiality.
Conclusions
Despite the limitations of our study, several findings
provide valuable information on how to improve metha-
done treatment and service delivery in Taiwan and per-
haps elsewhere. The HIV-positive patients in our
sample, all of whom received free treatment, were pre-
scribed higher doses of methadone and stayed longer in
treatment than the HIV-negative patients. Second, HCV
infection was prevalent among the heroin users, and all
the HIV-positive participants had contracted HCV.
Third, the HIV-negative patients were more likely to be
sexually active and less likely to use condoms during
sexual intercourse than the HIV-positive patients. How-
ever, 21(29.6%) and 7(10%) of the HIV-positive patients
continued to engage in sex- and drug-related risk beha-
vior even after being informed of their HIV status.
Fourth, there was a high prevalence of psychiatric
comorbidity among the heroin users, which highlights
the need to pay more clinical attention to the integra-
tion of methadone treatment and psychiatric medica-
tion. Changing psychiatrists’ perception of methadone
therapy from harm reduction to a treatment for heroin
dependence, and integrating psychosocial services and
HCV treatment in clinical practice, can improve treat-
ment outcomes related to the harmful effects of drug
use. Finally, more research is needed on the effect of
making methadone treatment free.
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